Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomas - PubMed (original) (raw)

Clinical Trial

Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomas

Gaurav D Shah et al. J Neurooncol. 2007 Nov.

Abstract

Reports suggest reasonable efficacy and minimal myelosuppression from combination imatinib and hydroxyurea for recurrent malignant glioma. We retrospectively reviewed 16 patients treated with this regimen who were evaluable for toxicity; 14 were also evaluable for response. The incidence of grade 3-4 hematologic toxicity was 25%. The best radiographic response, by Macdonald criteria, was partial response (PR) in three patients (21%), stable disease (SD) in four (29%), and progressive disease (PD) in seven (50%). One patient with a PR developed therapy-limiting hematologic toxicity on day 19 of treatment, progressing to grade 4 on day 64, and persisting until death on day 127 despite discontinuing both drugs. Another patient with PR and two of four patients with SD also developed grade 3 hematologic toxicity. All patients with grade 3-4 hematologic toxicity had disease control (PR or SD) as best radiographic response, whereas none with PD suffered grade 3-4 hematologic toxicity. Combining imatinib with hydroxyurea is effective in some patients with malignant glioma. However, myelosuppression can persist for months after discontinuing the regimen, precluding further chemotherapy. Disease control may also correlate with hematologic toxicity (p = 0.08), suggesting that glioma and marrow stem cells may share a common sensitivity to this chemotherapy regimen.

PubMed Disclaimer

Similar articles

• Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.
  Desjardins A, Quinn JA, Vredenburgh JJ, Sathornsumetee S, Friedman AH, Herndon JE, McLendon RE, Provenzale JM, Rich JN, Sampson JH, Gururangan S, Dowell JM, Salvado A, Friedman HS, Reardon DA. Desjardins A, et al. J Neurooncol. 2007 May;83(1):53-60. doi: 10.1007/s11060-006-9302-2. Epub 2007 Jan 24. J Neurooncol. 2007. PMID: 17245623 Clinical Trial.
• Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
  Reardon DA, Egorin MJ, Desjardins A, Vredenburgh JJ, Beumer JH, Lagattuta TF, Gururangan S, Herndon JE 2nd, Salvado AJ, Friedman HS. Reardon DA, et al. Cancer. 2009 May 15;115(10):2188-98. doi: 10.1002/cncr.24213. Cancer. 2009. PMID: 19248046 Free PMC article. Clinical Trial.
• Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.
  Reardon DA, Desjardins A, Vredenburgh JJ, Herndon JE 2nd, Coan A, Gururangan S, Peters KB, McLendon R, Sathornsumetee S, Rich JN, Lipp ES, Janney D, Friedman HS. Reardon DA, et al. Cancer. 2012 Oct 1;118(19):4759-67. doi: 10.1002/cncr.26541. Epub 2012 Feb 27. Cancer. 2012. PMID: 22371319 Free PMC article. Clinical Trial.
• Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
  Reardon DA, Egorin MJ, Quinn JA, Rich JN, Gururangan S, Vredenburgh JJ, Desjardins A, Sathornsumetee S, Provenzale JM, Herndon JE 2nd, Dowell JM, Badruddoja MA, McLendon RE, Lagattuta TF, Kicielinski KP, Dresemann G, Sampson JH, Friedman AH, Salvado AJ, Friedman HS. Reardon DA, et al. J Clin Oncol. 2005 Dec 20;23(36):9359-68. doi: 10.1200/JCO.2005.03.2185. J Clin Oncol. 2005. PMID: 16361636 Clinical Trial.
• The place of hydroxyurea in the treatment of primary brain tumors.
  Levin VA. Levin VA. Semin Oncol. 1992 Jun;19(3 Suppl 9):34-9. Semin Oncol. 1992. PMID: 1641655 Review.

Cited by

• Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
  Reardon DA, Desjardins A, Vredenburgh JJ, Sathornsumetee S, Rich JN, Quinn JA, Lagattuta TF, Egorin MJ, Gururangan S, McLendon R, Herndon JE 2nd, Friedman AH, Salvado AJ, Friedman HS. Reardon DA, et al. Neuro Oncol. 2008 Jun;10(3):330-40. doi: 10.1215/15228517-2008-003. Epub 2008 Mar 21. Neuro Oncol. 2008. PMID: 18359865 Free PMC article. Clinical Trial.
• Prognostic importance of temozolomide-induced neutropenia in glioblastoma, IDH-wildtype patients.
  Saito T, Sugiyama K, Hama S, Yamasaki F, Takayasu T, Nosaka R, Muragaki Y, Kawamata T, Kurisu K. Saito T, et al. Neurosurg Rev. 2018 Apr;41(2):621-628. doi: 10.1007/s10143-017-0903-3. Epub 2017 Sep 9. Neurosurg Rev. 2018. PMID: 28887717
• Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies.
  De Witt Hamer PC. De Witt Hamer PC. Neuro Oncol. 2010 Mar;12(3):304-16. doi: 10.1093/neuonc/nop068. Epub 2010 Feb 9. Neuro Oncol. 2010. PMID: 20167819 Free PMC article. Review.
• Systematic Review of Molecular Targeted Therapies for Adult-Type Diffuse Glioma: An Analysis of Clinical and Laboratory Studies.
  Muzyka L, Goff NK, Choudhary N, Koltz MT. Muzyka L, et al. Int J Mol Sci. 2023 Jun 21;24(13):10456. doi: 10.3390/ijms241310456. Int J Mol Sci. 2023. PMID: 37445633 Free PMC article. Review.

References

1. 1. Ann Oncol. 2001 Feb;12 (2):259-66 - PubMed
2. 1. Br J Haematol. 2002 Jul;118(1):144-6 - PubMed
3. 1. Arch Dis Child. 1999 Nov;81(5):437-9 - PubMed
4. 1. Cancer Cell. 2006 Dec;10 (6):454-6 - PubMed
5. 1. Neurology. 2004 Oct 12;63(7):1281-4 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program